|Bid||145.13 x 800|
|Ask||160.61 x 800|
|Day's Range||160.24 - 161.98|
|52 Week Range||90.64 - 161.98|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||55.37|
|Earnings Date||Jan. 29, 2020|
|Forward Dividend & Yield||1.56 (0.97%)|
|Ex-Dividend Date||Nov. 04, 2019|
|1y Target Est||142.00|
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders.
Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.
ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning at approximately 8:30 a.m. (Pacific Standard Time) at Westin St. Francis in San Francisco, CA.
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.
Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.
Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.
The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.
Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.
Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.
The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.